Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Available from LipoScience is NMR (nuclear magnetic resonance) lipoprotein particle testing using the company’s Vantera clinical analyzer through Mayo Medical Laboratories. NMR lipoprotein testing on the Vantera analyzer will be accessible to Mayo Clinic physicians and patients and other hospital clients of Mayo Medical Laboratories.
Beckman Coulter Genomics’ BRAF assay has been granted clinical laboratory licenses in Pennsylvania, Maryland, Rhode Island, and Massachusetts. CLIA certification, plus licensure in those states, allows Beckman to accept clinical samples for genetic sequencing—the most technically complex CLIA category—and provide those results to physicians to use in treating, diagnosing, and preventing disease in patients.
IncellDx has reached an agreement with Kindstar Global to offer its proprietary laboratory test for the detection of oncogenic HPV E6, E7 mRNA in China. Kindstar is a large esoteric diagnostic testing business.
Quest Diagnostics has entered into a definitive agreement to acquire laboratory-related clinical outreach service operations of Dignity Health, a hospital system based in California. Under the agreement, Quest will acquire operations through which Dignity Health provides outreach diagnostic information services to patients and physician offices in parts of California and Nevada.
Quidel Corp. has completed its acquisition of BioHelix Corp. According to terms of the deal, Quidel will pay BioHelix shareholders $10 million in cash, plus additional amounts in connection with an R&D earn-out based on the completion of a designated number of assays and a commercial earn-out dependent on product sales over a defined period.
Applied Spectral Imaging and BioDot have entered into an agreement under which both companies will engage in combined sales and marketing of a product that will directly link ASI’s GenASIs imaging and analysis instrument and BioDot’s CellWriter automated dispensing system for FISH and karyotyping.
Meridian Bioscience has received FDA clearance for its Mycoplasma pneumoniae molecular diagnostic test on the Illumigene platform. By amplifying the specific DNA for the detection of M. pneumoniae, the test provides a definitive result, thus helping to ensure that patients receive the appropriate antibiotic therapy in a timely manner.
Beckman Coulter Life Sciences’ VersaComp antibody capture bead kits are designed to set compensation for multicolor flow cytometry experiments by allowing researchers to use the same reagents as they do in their experiments.
BioMérieux’s Labguard is a real-time wireless, automated, temperature-monitoring solution for hospitals, laboratories, blood banks, and pharmacies. The solution features real-time, 24/7 Web-based monitoring with alarm display and notifications via SMS, e-mail, and fax. The solution has sensor probes for different applications, including temperature, humidity, pressure, and other physical parameters.
DiaSorin’s Liaison IGF-1 assay is a solution for full automation of growth factor testing on a random-access analyzer, for accurately monitoring growth dysfunctions. The company offers an extensive menu of reliable, fully automated chemiluminescent assays suitable for endocrinology clinics, reference laboratories, hospitals, and physician office laboratories. Patients benefit from rapid and accurate results, and laboratories benefit from fast turnaround time and ease of use with the Liaison assay product portfolio.
